Compare Allstate Corp (ALL) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allstate Corp vs BioNano Genomics Inc — how do they compare? Allstate Corp trades at $257.48 (market cap $66.31B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Allstate Corp is far larger — about 4854.3× BioNano Genomics Inc's market cap, and Allstate Corp pays a 1.65% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ALL | BNGO | |
|---|---|---|
Market Cap | $66.31B | $13.66M |
Sector | Financials | Health |
52-Week High | $275.11 | $4.92 |
52-Week Low | $190.00 | $1.06 |
Enterprise Value | $74.96B | $16.26M |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $256.62, down 4.84% over 24 hours, but maintains a bullish technical signal with strong fundamental performance. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, with revenue growth and improved underwriting profitability. Recent news highlights institutional buying and positive analyst coverage, though some caution exists on sustainability.
The outlook remains positive with a consensus price target of $266.47, offering potential upside. Key risks include sustainability of underwriting margins and macroeconomic sensitivity. Earnings momentum and valuation metrics support a favorable investment case, but investors should monitor competitive pressures and catastrophe loss trends.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
